ArticleJournal of dental sciences2026
Poly-ɛ-caprolactone/multi-wall carbon nanotube composites as osteoinductive scaffolds for alveolar bone regeneration.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Designing scaffolds to promote alveolar bone regeneration is a major challenge in dental practice. Among the desired properties of scaffolds, biocompatibility is crucial. Multi-walled carbon nanotubes (MWCNTs) possess high surface area and mechanical strength, enhancing the osteogenic properties of poly-ɛ-caprolactone (PCL). Therefore, this study evaluated the osteogenic potential of PCL/MWCNT scaffolds by incorporating varying weight percentages of MWCNTs (0.5-3 wt.%). Materials and methods: This study fabricated the scaffolds using a solvent-casting/particulate-leaching technique. Their physical and chemical properties were evaluated using contact angle (CA), porosity, pore size distribution, and Raman spectroscopy. In vitro biocompatibility was assessed via 3-(4,5-dimethylthiazole-2-Y1)-2,5-diphenyltetrazolium bromide (MTT) and alkaline phosphatase (ALP) assays using osteoblast-like cells (MG-63), and cell morphology cell morphology was observed using scanning electron microscopy (SEM). Results: The addition of MWCNTs to scaffolds improved their hydrophilicity and maintains a high porosity (>85 %) in most formulations. The Young's modulus (0.15-2.32 GPa) of PCL/MWCNT scaffolds containing different weight percentages of MWCNTs was comparable to that of human alveolar bone (1.0-3.3 GPa). PCL/MWCNT scaffolds containing 3 wt.% MWCNT exhibited the highest biocompatibility across all time points (days 1, 4, and 7). ALP activity, a marker of osteogenic differentiation, increased significantly over time, particularly at higher weight percentages MWCNT. Conclusion: The PCL/MWCNT scaffold, especially at a 3 wt.% MWCNT, demonstrated excellent biocompatibility, porosity, and osteoinductive potential, making it a promising candidate for alveolar bone tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.